Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.

Schuster Bruce C, Brhlikova P, Heath J, McGettigan P.

PLoS Med. 2019 Sep 10;16(9):e1002873. doi: 10.1371/journal.pmed.1002873. eCollection 2019 Sep.

2.

Correction to: Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.

McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, Kurz X, Mol PGM.

Drug Saf. 2019 Sep 5. doi: 10.1007/s40264-019-00859-6. [Epub ahead of print]

PMID:
31489581
3.

Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.

McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, Kurz X, Mol PGM.

Drug Saf. 2019 Jul 13. doi: 10.1007/s40264-019-00848-9. [Epub ahead of print] Erratum in: Drug Saf. 2019 Sep 5;:.

PMID:
31302896
4.

Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.

Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X.

JAMA Neurol. 2019 Jul 1;76(7):827-833. doi: 10.1001/jamaneurol.2019.0887.

PMID:
31034074
5.

Barriers and Opportunities for Use of Patient Registries in Medicines Regulation.

Olmo CA, McGettigan P, Kurz X.

Clin Pharmacol Ther. 2019 Jul;106(1):39-42. doi: 10.1002/cpt.1414. Epub 2019 Apr 10. No abstract available.

6.

Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.

Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X.

Clin Drug Investig. 2019 Feb;39(2):215. doi: 10.1007/s40261-019-00755-y.

7.

Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy-A nationwide study in patients with osteoarthritis.

Barcella CA, Lamberts M, McGettigan P, Fosbøl EL, Lindhardsen J, Torp-Pedersen C, Gislason GH, Olsen AS.

Basic Clin Pharmacol Toxicol. 2019 May;124(5):629-641. doi: 10.1111/bcpt.13182. Epub 2019 Jan 4.

PMID:
30484960
8.

Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.

Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X.

Clin Drug Investig. 2019 Feb;39(2):205-213. doi: 10.1007/s40261-018-0729-y. Erratum in: Clin Drug Investig. 2019 Feb 6;:.

9.

Adverse drug reactions.

Ferner RE, McGettigan P.

BMJ. 2018 Nov 6;363:k4051. doi: 10.1136/bmj.k4051. No abstract available. Erratum in: BMJ. 2018 Nov 12;363:k4777.

PMID:
30401691
10.

Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.

Pacurariu A, Plueschke K, McGettigan P, Morales DR, Slattery J, Vogl D, Goedecke T, Kurz X, Cave A.

BMJ Open. 2018 Sep 5;8(9):e023090. doi: 10.1136/bmjopen-2018-023090. Erratum in: BMJ Open. 2019 Feb 22;8(11):e023090corr1.

11.

EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making.

Plueschke K, McGettigan P, Pacurariu A, Kurz X, Cave A.

BMJ Open. 2018 Jun 14;8(6):e021864. doi: 10.1136/bmjopen-2018-021864.

12.

Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India.

McGettigan P, Roderick P, Kadam A, Pollock A.

Br J Clin Pharmacol. 2019 Jan;85(1):59-70. doi: 10.1111/bcp.13503. Epub 2018 Feb 21.

PMID:
29397576
13.

Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship.

McGettigan P, Roderick P, Kadam A, Pollock AM.

Lancet Glob Health. 2017 Nov;5(11):e1075-e1076. doi: 10.1016/S2214-109X(17)30365-0. No abstract available.

14.

NSAIDs for high-risk patients: none, celecoxib, or naproxen?

McGettigan P, Olsen AS.

Lancet. 2017 Jun 17;389(10087):2351-2352. doi: 10.1016/S0140-6736(17)30980-7. Epub 2017 Apr 11. No abstract available.

PMID:
28410794
15.

PCSK9 inhibitors for hypercholesterolaemia.

McGettigan P, Ferner RE.

BMJ. 2017 Jan 19;356:j188. doi: 10.1136/bmj.j188. No abstract available.

PMID:
28104607
16.

Presence of Medical Students and Length of Stay in the Emergency Department.

McGettigan P, McKendree J.

JAMA. 2016 May 10;315(18):2019. doi: 10.1001/jama.2016.1577. No abstract available.

PMID:
27163996
18.

Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study.

Schjerning Olsen AM, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbøl E, Køber L, Torp-Pedersen C, Lamberts M.

BMJ. 2015 Oct 19;351:h5096. doi: 10.1136/bmj.h5096.

19.

Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs.

McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM.

PLoS Med. 2015 May 12;12(5):e1001826; discussion e1001826. doi: 10.1371/journal.pmed.1001826. eCollection 2015 May.

20.

Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction.

Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Hansen ML, Køber L, Torp-Pedersen C, Lamberts M.

JAMA. 2015 Feb 24;313(8):805-14. doi: 10.1001/jama.2015.0809.

PMID:
25710657
21.

Department of Health's misguided alert recommending neuraminidase inhibitors for flu.

McGettigan P, Pollock A, Herxheimer A.

BMJ. 2014 Feb 19;348:g1594. doi: 10.1136/bmj.g1594. No abstract available.

PMID:
24554184
22.

India should introduce a new Drugs Act.

Roderick P, Mahajan R, McGettigan P, Pollock AM.

Lancet. 2014 Jan 18;383(9913):203-6. No abstract available.

PMID:
24449942
23.

Problems of polypharmacy.

Herxheimer A, McGettigan P.

BMJ. 2013 Dec 23;347:f7500. doi: 10.1136/bmj.f7500. No abstract available.

PMID:
24366533
24.
25.

Identifying attributes required by Foundation Year 1 doctors in multidisciplinary teams: a tool for performance evaluation.

McGettigan P, McKendree J, Reed N, Holborow S, Walsh CD, Mace T.

BMJ Qual Saf. 2013 Mar;22(3):225-32. doi: 10.1136/bmjqs-2012-001418. Epub 2013 Jan 29.

PMID:
23362506
26.

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.

McGettigan P, Henry D.

PLoS Med. 2011 Sep;8(9):e1001098. doi: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27. Review.

27.

Clinical toxicology and drug regulation: a United Kingdom perspective.

Waring WS, McGettigan P.

Clin Toxicol (Phila). 2011 Jul;49(6):452-6. doi: 10.3109/15563650.2011.594054.

PMID:
21824056
28.

The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.

McGettigan P, Lincz LF, Attia J, McElduff P, Bissett L, Peel R, Stokes B, Hancock S, Henderson K, Seldon M, Henry D.

Br J Clin Pharmacol. 2011 Oct;72(4):707-14. doi: 10.1111/j.1365-2125.2011.03957.x.

29.

Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data.

Ringland C, Mant A, McGettigan P, Mitchell P, Kelman C, Buckley N, Pearson SA.

Br J Clin Pharmacol. 2008 Nov;66(5):682-8. doi: 10.1111/j.1365-2125.2008.03253.x. Epub 2008 Jul 8.

30.

Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.

McGettigan P, Han P, Jones L, Whitaker D, Henry D.

Br J Clin Pharmacol. 2008 Jun;65(6):927-34. doi: 10.1111/j.1365-2125.2008.03121.x. Epub 2008 Apr 1.

31.

The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis.

Attia J, Thakkinstian A, Wang Y, Lincz L, Parsons M, Sturm J, McGettigan P, Scott R, Meldrum C, Levi C.

J Stroke Cerebrovasc Dis. 2007 Jul-Aug;16(4):173-9.

PMID:
17689414
32.

Selective COX-2 inhibitors: a promise unfulfilled?

Henry D, McGettigan P.

Gastroenterology. 2007 Feb;132(2):790-4. No abstract available.

PMID:
17261306
33.
34.

Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships.

McGettigan P, Han P, Henry D.

Br J Clin Pharmacol. 2006 Sep;62(3):358-65.

35.

What price research?

Robertson J, McGettigan P.

Aust Fam Physician. 2006 Jan-Feb;35(1-2):7. No abstract available.

PMID:
16502541
36.

Response rates and representativeness: a lottery incentive improves physician survey return rates.

Robertson J, Walkom EJ, McGettigan P.

Pharmacoepidemiol Drug Saf. 2005 Aug;14(8):571-7.

PMID:
15937989
37.

Medical research and the news media.

McGettigan P, Henry D.

N Engl J Med. 2005 Feb 24;352(8):838-9; author reply 838-9. No abstract available.

PMID:
15736294
38.

Describing treatment effects to patients.

Moxey A, O'Connell D, McGettigan P, Henry D.

J Gen Intern Med. 2003 Nov;18(11):948-59. Review.

39.

Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs.

Henry D, McGettigan P.

Int J Clin Pract Suppl. 2003 Apr;(135):43-9. Review.

PMID:
12723747
40.

Concomitant overdosing of other drugs in patients with paracetamol poisoning.

Isbister GK, Whyte IM, Downes F, Dawson AH, McGettigan P.

Br J Clin Pharmacol. 2003 Mar;55(3):325; author reply 326. No abstract available.

41.

Upper gastrointestinal event risk with COX-2 inhibitors depended on known risk factors.

Henry D, McGettigan P.

ACP J Club. 2003 Mar-Apr;138(2):51. No abstract available.

PMID:
12614136
42.

Hyperbaric oxygen for acute carbon monoxide poisoning.

Isbister GK, McGettigan P, Harris I.

N Engl J Med. 2003 Feb 6;348(6):557-60; author reply 557-60. No abstract available.

PMID:
12572577
43.

Adolescent depression.

McGettigan P, Isbister GK, Whyte IM.

N Engl J Med. 2003 Jan 30;348(5):473-4; author reply 473-4. No abstract available.

PMID:
12556553

Supplemental Content

Loading ...
Support Center